These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
776 related articles for article (PubMed ID: 30295933)
41. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy]. Sekijima Y Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679 [TBL] [Abstract][Full Text] [Related]
42. Familial amyloid polyneuropathy: When does it stop to be asymptomatic and need a treatment? Adams D; Beaudonnet G; Adam C; Lacroix C; Théaudin M; Cauquil C; Labeyrie C Rev Neurol (Paris); 2016 Oct; 172(10):645-652. PubMed ID: 27663057 [TBL] [Abstract][Full Text] [Related]
44. [Transthyretin familial amyloid polyneuropathy - three Hungarian cases with rare mutations (His88Arg and Phe33Leu)]. Csillik A; Pozsonyi Z; Soós K; Balogh I; Bodó I; Arányi Z Ideggyogy Sz; 2016 Jul; 69(7-8):245-253. PubMed ID: 29465889 [TBL] [Abstract][Full Text] [Related]
45. The morphology of amyloid fibrils and their impact on tissue damage in hereditary transthyretin amyloidosis: An ultrastructural study. Koike H; Nishi R; Ikeda S; Kawagashira Y; Iijima M; Sakurai T; Shimohata T; Katsuno M; Sobue G J Neurol Sci; 2018 Nov; 394():99-106. PubMed ID: 30243104 [TBL] [Abstract][Full Text] [Related]
46. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study. Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161 [TBL] [Abstract][Full Text] [Related]
47. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Koike H; Misu K; Sugiura M; Iijima M; Mori K; Yamamoto M; Hattori N; Mukai E; Ando Y; Ikeda S; Sobue G Neurology; 2004 Jul; 63(1):129-38. PubMed ID: 15249622 [TBL] [Abstract][Full Text] [Related]
49. A natural history analysis of asymptomatic Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L; Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447 [TBL] [Abstract][Full Text] [Related]
50. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Adams D; Koike H; Slama M; Coelho T Nat Rev Neurol; 2019 Jul; 15(7):387-404. PubMed ID: 31209302 [TBL] [Abstract][Full Text] [Related]
51. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma. Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187 [TBL] [Abstract][Full Text] [Related]
52. Novel transthyretin gene mutation in familial amyloid neuropathy in India: Case. Rohatgi S; Nirhale S; Manohar P; Rao P; Naphade P; Khan FMA; Dave D; Sravya Kotaru VV; Gupta S; Gitay A; Dubey P Ann Afr Med; 2022; 21(3):296-298. PubMed ID: 36204920 [TBL] [Abstract][Full Text] [Related]
53. Phenome-wide association study of TTR and RBP4 genes in 361,194 individuals reveals novel insights in the genetics of hereditary and wildtype transthyretin amyloidoses. De Lillo A; De Angelis F; Di Girolamo M; Luigetti M; Frusconi S; Manfellotto D; Fuciarelli M; Polimanti R Hum Genet; 2019 Dec; 138(11-12):1331-1340. PubMed ID: 31659433 [TBL] [Abstract][Full Text] [Related]
54. Upper limb neuropathy such as carpal tunnel syndrome as an initial manifestation of ATTR Val30Met familial amyloid polyneuropathy. Tojo K; Tsuchiya-Suzuki A; Sekijima Y; Morita H; Sumita N; Ikeda S Amyloid; 2010 Mar; 17(1):32-5. PubMed ID: 20132088 [TBL] [Abstract][Full Text] [Related]
55. Pathological, biochemical, and biophysical characteristics of the transthyretin variant Y114H (p.Y134H) explain its very mild clinical phenotype. Sekijima Y; Campos RI; Hammarström P; Nilsson KP; Yoshinaga T; Nagamatsu K; Yazaki M; Kametani F; Ikeda S J Peripher Nerv Syst; 2015 Dec; 20(4):372-9. PubMed ID: 26306725 [TBL] [Abstract][Full Text] [Related]
56. [What gnaws at the heart and gets on the nerves]. Kristen AV Internist (Berl); 2018 Nov; 59(11):1208-1213. PubMed ID: 30039176 [TBL] [Abstract][Full Text] [Related]
57. Assessment of autonomic innervation of the foot in familial amyloid polyneuropathy. Zouari HG; Ng Wing Tin S; Wahab A; Damy T; Lefaucheur JP Eur J Neurol; 2019 Jan; 26(1):94-e10. PubMed ID: 30102818 [TBL] [Abstract][Full Text] [Related]
58. [Neurological manifestations of ATTR amyloidosis]. Pernice HF; Hahn K Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967 [TBL] [Abstract][Full Text] [Related]
59. Clinical and genetic findings in eight Israeli patients with transthyretin-associated familial amyloid polyneuropathy. Leibou L; Frand J; Sadeh M; Lossos A; Kremer E; Livneh A; Yarnitsky D; Herman O; Dabby R Isr Med Assoc J; 2012 Nov; 14(11):662-5. PubMed ID: 23240369 [TBL] [Abstract][Full Text] [Related]
60. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. Cortese A; Vita G; Luigetti M; Russo M; Bisogni G; Sabatelli M; Manganelli F; Santoro L; Cavallaro T; Fabrizi GM; Schenone A; Grandis M; Gemelli C; Mauro A; Pradotto LG; Gentile L; Stancanelli C; Lozza A; Perlini S; Piscosquito G; Calabrese D; Mazzeo A; Obici L; Pareyson D J Neurol; 2016 May; 263(5):916-924. PubMed ID: 26984605 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]